China-United States Research Collaborations in Antimicrobial Resistance.
Journal Article
A strong synergy can result from China-US antimicrobial resistance (AMR) collaborations given similarities and differences between their respective healthcare systems and research infrastructures. The Antibacterial Resistance Leadership Group has employed a model of realistic growth, starting with a feasible, relatively low-resource observational study in a critical priority pathogen. This and other observational studies will provide vital scientific information required for the rational design of future interventional trials. In addition, it provides a mutual, low-risk opportunity for determining the strengths and opportunities of the research collaboration. Issues identified during the observational studies can be addressed prior to the initiation of high-resource interventional studies. Collaborative clinical AMR studies between China and the United States have tremendous potential to decrease AMR rates, improve responsible antibiotic use, and ultimately improve the lives of patients in both countries.
Full Text
Duke Authors
Cited Authors
- van Duin, D; Gu, P; Dong, J; Paff, M; Arias, RM; Evans, B; Yu, Y; Li, L; Zhang, F; Liu, Z; Cao, B; Fowler, VG; Wang, M
Published Date
- November 13, 2018
Published In
- Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Volume / Issue
- 67 / suppl_2
Start / End Page
- S142 - S145
PubMed ID
- 30423056
Pubmed Central ID
- 30423056
Electronic International Standard Serial Number (EISSN)
- 1537-6591
Digital Object Identifier (DOI)
- 10.1093/cid/ciy694
Language
- eng
Conference Location
- United States